---
title: "BIOMERICA INC FY 2026: Revenue $4.45M, EPS $(1.30) — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297562866.md"
description: "BIOMERICA INC reported FY 2026 revenue of $4.45M, a 16% decline from FY 2025, driven by lower clinical lab and manufacturing volumes. The company posted a net loss of $3.78M and diluted EPS of $(1.30), both improvements over the previous year's figures. Key developments include securing Medicare reimbursement for inFoods® IBS, entering agreements with Henry Schein and a CDMO, and reducing R&D spending as programs move toward commercialization."
datetime: "2026-08-31T21:05:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297562866.md)
  - [en](https://longbridge.com/en/news/297562866.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297562866.md)
generator: "portal-rs"
---

# BIOMERICA INC FY 2026: Revenue $4.45M, EPS $(1.30) — 10-K Summary

BIOMERICA INC reported fiscal 2026 revenue of $4.45M and a net loss of $3.78M, with diluted loss per share of $(1.30), an improvement versus fiscal 2025 results as revenue declined and losses narrowed year over year.

**Financial Highlights**

-   Revenue was $4.45M for FY 2026, down from $5.31M in FY 2025 (16%).
-   Net income: Net loss $3.78M for FY 2026, improved from net loss $4.97M in FY 2025 (loss narrowed ~24%).
-   Diluted earnings per share: $(1.30) per share for FY 2026, improved from $(2.16) per share in FY 2025.

**Business Highlights**

-   Revenue decline driven by lower clinical lab, over‑the‑counter and contract manufacturing volumes.
-   Phased commercialization of inFoods® IBS concentrated on gastroenterology physicians, alongside lab sales of hp+detect™ in the U.S. and U.K.
-   Secured a CPT PLA code and a national Medicare rate of $300 for inFoods® IBS; initial Medicare claims have been paid.
-   Entered a marketing services agreement with Henry Schein and a CDMO master services agreement targeting more than $1.75M in development fees.
-   Reduced R&D spending as programs moved toward commercialization and management is pursuing improved plant utilization through contract manufacturing work.

Original SEC Filing: BIOMERICA INC \[ BMRA \] - 10-K - Aug. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BMRA.US](https://longbridge.com/en/quote/BMRA.US.md)
- [HSIC.US](https://longbridge.com/en/quote/HSIC.US.md)

## Related News & Research

- [Biomerica CEO Zackary S. Irani reports acquisition of $50,000 common shares](https://longbridge.com/en/news/297235006.md)
- [Biomerica FY26 net sales drop 16% to $4.45 million; dividend, interest and other income more than doubled to $1.23 million](https://longbridge.com/en/news/297561919.md)
- [Biomerica Enters Securities Purchase Agreement for Private Placement With Investors](https://longbridge.com/en/news/297088565.md)
- [Scinai Immunotherapeutics: Expanded CDMO platform drives growth, but operating losses persist as revenue scales](https://longbridge.com/en/news/297069758.md)
- [LyondellBasell announces dividend of R$ 1.72 per unit for 3Q 2026](https://longbridge.com/en/news/297814383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**